Table 3.
Baseline characteristics of those with history of antineoplastic therapy vs no antineoplastic therapy.
| Before PSM |
After PSM |
|||||
|---|---|---|---|---|---|---|
| No antineoplastic therapy N = 402 |
Antineoplastic therapy N = 111 | Standardized difference | No antineoplastic therapy N = 107 |
Antineoplastic therapy N = 107 | Standardized difference | |
| Baseline Characteristics | ||||||
| Age | 78.2 ± 9.4 | 76.5 ± 9.9 | 0.17 | 78.1 ± 9.6 | 77.3 ± 8.9 | 0.08 |
| Male | 231 (57.5 %) | 56 (50.5 %) | 0.14 | 49 (45.8 %) | 54 (50.5 %) | 0.09 |
| Female | 171 (42.5 %) | 55 (49.5 %) | 0.14 | 58 (54.2 %) | 53 (49.5 %) | 0.09 |
| White | 352 (87.6 %) | 96 (86.5 %) | 0.03 | 94 (87.9 %) | 93 (86.90 %) | 0.02 |
| Asian | 10 (2.5 %) | 10 (9.0 %) | 0.28 | 10 (9.3 %) | 10 (9.3 %) | <0.001 |
| Black | 29 (7.2 %) | 10 (9.0 %) | 0.06 | 10 (9.3 %) | 10 (9.3 %) | <0.001 |
| Hispanic | 10 (2.5 %) | 10 (9.0 %) | 0.28 | 10 (9.3 %) | 10 (9.3 %) | <0.011 |
| Not Hispanic | 371 (90.52 %) | 101 (92.3 %) | 0.04 | 98 (91.6 %) | 99 (92.5 %) | 0.03 |
| Co-Morbid Conditions | ||||||
| Hyperlipidemia | 286 (79.3.%) | 76 (68.5 %) | 0.18 | 83 (77.6 %) | 85 (79.4 %) | 0.04 |
| Hypertensive diseases | 350 (87.1 %) | 107 (96.4 %) | 0.34 | 104 (97.2 %) | 103 (96.2 %) | 0.05 |
| Ischemic heart diseases | 316 (76.8 %) | 90 (81.1 %) | 0.06 | 86 (80.4 %) | 88 (82.2 %) | 0.04 |
| Atrial fibrillation and flutter | 285 (70.9 %) | 76 (68.5 %) | 0.05 | 81 (75.7 %) | 75 (70.1 %) | 0.12 |
| Cardiomyopathy | 157 (39.1 %) | 43 (38.7 %) | 0.006 | 37 (34.6 %) | 42 (39.3 %) | 0.09 |
| Diabetes mellitus | 121 (30.1 %) | 42 (37.8 %) | 0.16 | 33 (30.8 %) | 40 (37.4 %) | 0.13 |
| Laboratory Data | ||||||
| Creatinine | 1.4 ± 0.8 | 1.3 ± 0.7 | 0.16 | 1.3 ± 0.6 | 1.2 ± 0.60 | 0.14 |
| Hemoglobin | 11.0 ± 2.4 | 11.2 ± 2.2 | 0.09 | 11.1 ± 2.3 | 11.1 ± 2.4 | 0.02 |
| Sodium | 138.9 ± 3.9 | 138.4 ± 3.7 | 0.13 | 139.0 ± 3.6 | 138.5 ± 3.6 | 0.215 |
| Platelets | 188.4 ± 74.6 | 185.67 ± 75.7 | 0.03 | 193.4 ± 78.0 | 187.3 ± 75.9 | 0.07 |
| LDL | 81.5 ± 37.5 | 81.2 ± 32.3 | 0.009 | 81.3 ± 40.2 | 81.90 ± 32.3 | 0.01 |
| Hemoglobin A1c | 6.0 ± 1.1 | 6.3 ± 2.2 | 0.18 | 6.0 ± 0.8 | 6.3 ± 2.3 | 0.18 |
| BMI | 26.3 ± 6.3 | 25.9 ± 6.7 | 0.06 | 25.9 ± 6.4 | 25.6 ± 6.5 | 0.03 |
| LVEF ≤ 40 % | 54 (14.4 %) | 16 (14.4 %) | 0.02 | 16 (15.0 %) | 15 (14.0 %) | 0.02 |
| Medications | ||||||
| Diuretics | 345 (85.8 %) | 100 (90.10 %) | 0.13 | 99 (92.5 %) | 96 (89.7 %) | 0.09 |
| Beta Blockers | 337 (83.8 %) | 98 (88.3 %) | 0.12 | 97 (90.7 %) | 94 (87.9 %) | 0.09 |
| Antilipemic agents | 280 (69.7 %) | 77 (69.4 %) | 0.006 | 75 (70.1 %) | 75 (70.1 %) | <0.001 |
| ACEI | 180 (44.80 %) | 60 (54.1 %) | 0.18 | 56 (52.3 %) | 58 (54.2 %) | 0.03 |
| ARB | 121 (30.1 %) | 31 (27.9 %) | 0.04 | 29 (27.1 %) | 31 (29.0 %) | 0.04 |
| Sacubitril | 29 (7.2 %) | 10 (9.0 %) | 0.06 | 10 (9.30 %) | 10 (9.30 %) | <0.001 |
| Anticoagulants | 373 (92.8 %) | 107 (96.4 %) | 0.16 | 101 (94.4 %) | 103 (96.3 %) | 0.08 |
Demonstrates the baseline characteristics of the patients who had cancer and underwent TEER along with a history of receiving antineoplastic therapy Patient characteristics are compared between two cohorts (Antineoplastic therapy vs No antineoplastic therapy) before and after propensity score matching.
Abbreviations: ACE inhibitors, angiotensin converting enzyme inhibitors, ARB, Aldosterone receptor blockers, AF, Atrial fibrillation, BMI, Body Mass Index, CKD, Chronic kidney disease, HBA1c, Hemoglobin A1c, LDL, Low Density Lipoprotein, LVEF, Left Ventricular Ejection Fraction.